Share Prices & Company Research

Stockbroking

Fusion Antibodies Ord 4p

Current Price 62.85p Bid 65.00p Ask 67.00p Change 0.00%
Last Updated: 19/09/2019 22:13. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Fusion Antibodies plc is a Belfast based contract research organisation (CRO) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced over 250 antibodies and successfully completed over 100 humanisation projects for its international, blue-chip client base, which includes eight of the top 10 global pharmaceutical companies by revenue. The Company was established in 2001 as a spin out from Queen's University Belfast. It was initially a drug development business but revised its operations to focus on CRO work in 2011. The Company has a highly experienced management team with a combined 47 years' experience in the biopharma industry.

Financial Highlights Year Ended 31/03/2019

Turnover
£2.18m
Operating Profit
£-1.51m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-11.58

Key Personnel

Dr Paul Gerard Kerr Kerr
Chief Executive Officer
James Alexander Fair
Chief Financial Officer
Dr Richard John Buick
Chief Technology Officer
Dr Simon Gordon Douglas
Executive Chairman
Timothy William Watts
Non-Executive Director
Colin James Walsh
Non-Executive Director
Dr Alan Mawson
Non-Executive Director
Sonya Maria Ferguson
Non-Executive Director

Stock Details

EPIC
FAB
ISIN
GB00BDQZGK16
Shares in Issue
22,091,192
Market cap
£14.58m

Analyst Views (0)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
0.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
66.00p
Bid Price
65.00p
Ask Price
67.00p
Volume
0
Change Today
0.00p
% Change Today
0.00%
Open
0.00p
Previous Close
66.00p
Intraday High
0.00p
Intraday Low
0.00p
52 Week High
85.00p
52 Week Low
25.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Fusion Antibodies  Ord 4p Intra-day Chart

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Mar 2019
31 Mar 2018
Tangible Assets
1.6
0.6
Intangible Assets & Goodwill
0.0
0.0
Investments & Other Non-Current Assets
1.3
1.2
Total Non-Current Assets
2.9
1.7
Inventory
0.2
0.1
Trade & Receivables
1.1
0.9
Cash & Receivables
2.0
4.5
Other Current Assets & Assets Held for Resale
0.0
0.0
Total Assets
6.2
7.2

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Mar 2019
31 Mar 2018
Short Term Liabilities
0.8
0.6
Long Term Liabilities
0.1
0.1
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
0.9
0.6

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Mar 2019
31 Mar 2018
Net Assets
5.4
6.6

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Mar 2019
31 Mar 2018
Share Capital
0.9
0.9
Minority Interests
0.0
0.0
Retained Earnings
-0.4
0.8
Share Premium Account
4.9
4.9
Other Equity
0.0
0.0
Total Equity
5.4
6.6

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Mar 2019
31 Mar 2018
Cashflow from Operating Activities
-1.1
0.1
Cashflow Before Financing
-2.5
-0.4
Increase / Decrease in Cash
-2.5
4.2

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Mar 2019
31 Mar 2018
Turnover
2.2
2.7
Cost of Sales
1.4
1.2
Gross Profit
0.8
1.5
Operating Profit
-1.5
-0.7
Pre-Tax Profit
-1.5
-0.7
Profit / Loss for the Year
-1.3
-0.7
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.